Severe Group A Streptococcus Infection among Children, France, 2022–2024

IF 6.6 2区医学 Q1 IMMUNOLOGY

Emerging Infectious Diseases Pub Date : 2025-08-21 DOI:10.3201/eid3109.250245

Montserrat Sierra Colomina, Alix Flamant, Guillaume Le Balle, Jérémie F. Cohen, Lionel Berthomieu, Stéphane Leteurtre, Yves Gillet, Etienne Javouhey, Stéphane Bechet, Corinne Levy, Robert Cohen, Agnès Ferroni, Damien Dubois, Miguel Angel Hernandez Martinez, Céline Plainvert, Asmaa Tazi, Camille Brehin

{"title":"Severe Group A Streptococcus Infection among Children, France, 2022–2024","authors":"Montserrat Sierra Colomina, Alix Flamant, Guillaume Le Balle, Jérémie F. Cohen, Lionel Berthomieu, Stéphane Leteurtre, Yves Gillet, Etienne Javouhey, Stéphane Bechet, Corinne Levy, Robert Cohen, Agnès Ferroni, Damien Dubois, Miguel Angel Hernandez Martinez, Céline Plainvert, Asmaa Tazi, Camille Brehin","doi":"10.3201/eid3109.250245","DOIUrl":null,"url":null,"abstract":" Suggested citation for this articleSierra Colomina M, Flamant A, Le Balle G, Cohen JF, Berthomieu L, Leteurtre S, et al. Severe group A Streptococcus infection among children, France, 2022–2024. Emerg Infect Dis. 2025 Sep [date cited]. https://doi.org/10.3201/eid3109.250245\nGroup A Streptococcus infections have increased in Europe since September 2022. The French Pediatric Intensive Care and French Pediatric Infectious Diseases expert groups conducted a retrospective and prospective study of children who had severe group A Streptococcus infections during September 1, 2022–April 1, 2024, across 34 hospitals in France. A total of 402 pediatric patients (median age 4 [interquartile range 2–7.5] years; 42% girls, 58% boys) were enrolled. Cases were characterized by a low proportion of severe skin and soft tissue infections (16%), predominance of severe upper and lower respiratory tract infections (55%), and a 3.5% case-fatality rate. In multivariate analysis, hydrocortisone, corticosteroid, and vasopressor therapies were significantly associated with major sequelae or death. Molecular analysis revealed emm1 (73.0%) and emm12 (10.8%) strains; the M1UK clone represented 50% of emm1 strains. Clinicians, researchers, and public health authorities must collaborate to mitigate the effects of GAS on child health.","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":"9 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3109.250245","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Suggested citation for this article

Sierra Colomina M, Flamant A, Le Balle G, Cohen JF, Berthomieu L, Leteurtre S, et al. Severe group A Streptococcus infection among children, France, 2022–2024. Emerg Infect Dis. 2025 Sep [date cited]. https://doi.org/10.3201/eid3109.250245

Group A Streptococcus infections have increased in Europe since September 2022. The French Pediatric Intensive Care and French Pediatric Infectious Diseases expert groups conducted a retrospective and prospective study of children who had severe group A Streptococcus infections during September 1, 2022–April 1, 2024, across 34 hospitals in France. A total of 402 pediatric patients (median age 4 [interquartile range 2–7.5] years; 42% girls, 58% boys) were enrolled. Cases were characterized by a low proportion of severe skin and soft tissue infections (16%), predominance of severe upper and lower respiratory tract infections (55%), and a 3.5% case-fatality rate. In multivariate analysis, hydrocortisone, corticosteroid, and vasopressor therapies were significantly associated with major sequelae or death. Molecular analysis revealed emm1 (73.0%) and emm12 (10.8%) strains; the M1_UK clone represented 50% of emm1 strains. Clinicians, researchers, and public health authorities must collaborate to mitigate the effects of GAS on child health.

查看原文本刊更多论文

法国儿童严重A群链球菌感染，2022-2024

ierra Colomina M, Flamant A, Le Balle G, Cohen JF, Berthomieu L, Leteurtre S，等。法国儿童严重的A组链球菌感染，2022-2024。新兴传染病。2025年9月[引用日期]。https://doi.org/10.3201/eid3109.250245Group自2022年9月以来，欧洲的链球菌感染有所增加。法国儿科重症监护和法国儿科传染病专家组对法国34家医院在2022年9月1日至2024年4月1日期间发生严重a组链球菌感染的儿童进行了回顾性和前瞻性研究。共纳入402例儿科患者（中位年龄4岁[四分位数间距2-7.5]岁，42%为女孩，58%为男孩）。病例的特点是严重皮肤和软组织感染比例低（16%），主要是严重上呼吸道和下呼吸道感染（55%），病死率为3.5%。在多变量分析中，氢化可的松、皮质类固醇和血管加压素治疗与主要后遗症或死亡显著相关。分子分析显示emm1（73.0%）和emm12（10.8%）菌株；M1UK克隆占emm1菌株的50%。临床医生、研究人员和公共卫生当局必须合作，减轻气体对儿童健康的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging Infectious Diseases 医学-传染病学

CiteScore

17.30

自引率

1.70%

发文量

505

审稿时长

1 months

期刊介绍： Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination. Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.